靶向细菌感染的放射性药物的开发与验证
国际原子能机构于2022年在维也纳总部召开技术会议,17名来自12个国家的专家参会,聚焦细菌感染的放射性药物显像。会议讨论并评估了多种放射性药物的优缺点及不同显像方法的科学原理,主要目标是理解为何感染靶向放射性示踪剂临床应用少。文章总结了专家共识及当前研究标准的意见与建议。
要点
- 国际原子能机构2022年会议汇聚12国17名专家,聚焦细菌感染放射性药物显像。
- 会议评估多种放射性药物优缺点,探讨驱动不同显像方法的科学原理。
- 文章总结感染显像放射性药物开发现状的共识及当前研究标准的意见与建议。
核心结论
- 文章总结了参会科学家和国家就感染显像放射性药物开发现状达成的共识,并包含对该领域当前研究标准的意见与建议。
研究设计与样本
- 国际原子能机构于2022年在奥地利维也纳总部组织技术会议,17名来自12个国家的专家参会,研究涵盖放射性标记感染显像药物的开发与使用。
主要发现
- 会议主要聚焦细菌病原体,讨论并评估了多种放射性药物的优缺点以及驱动各种显像方法的科学原理。
- 会议主要目标是理解为何感染靶向放射性示踪剂临床应用少,尽管亟需更好地表征细菌感染。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The International Atomic Energy Agency organized a technical meeting at its headquarters in Vienna, Austria, in 2022 that included 17 experts representing 12 countries, whose research spanned the development and use of radiolabeled agents for imaging infection. The meeting focused largely on bacterial pathogens. The group discussed and evaluated the advantages and disadvantages of several radiopharmaceuticals, as well as the science driving various imaging approaches. The main objective was to understand why few infection-targeted radiotracers are used in clinical practice despite the urgent need to better characterize bacterial infections. This article summarizes the resulting consensus, at least among the included scientists and countries, on the current status of radiopharmaceutical development for infection imaging. Also included are opinions and recommendations regarding current research standards in this area. This and future International Atomic Energy Agency-sponsored collaborations will advance the goal of providing the medical community with innovative, practical tools for the specific image-based diagnosis of infection.
引用
- Signore A, Ordonez AA, Arjun C, et al. The Development and Validation of Radiopharmaceuticals Targeting Bacterial Infection. J Nucl Med. 2023. PMID: 37770110. doi:10.2967/jnumed.123.265906
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。